Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAESCs Transplantation for Parkinson's Disease
NCT05691114Phase 1Recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human amniotic epithelial stem cells in Parkinson's disease (PD), sponsored by Shanghai East Hospital. Primary endpoints: Dose Limiting Toxicity at 12 months and Adverse Events at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05691114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691114.